Verrica Q3 Revenue Up 58% to $5.7M; Runway Extended Into Q4 2027
VRCA sits 20% above its 52-week low of $3.08.
Summary
Verrica posted record Q3 YCANTH revenue of $5.7 million, up 57.9% year over year, and said full access to its $27.5 million credit facility extends cash runway into Q4 2027, past both common-warts Phase 3 readouts.
Key Events · Earnings and Guidance · VRCA
-
Record Q3 YCANTH Revenue
U.S. YCANTH net product revenue was $5.7 million, up 11.9% sequentially and 57.9% year over year; total revenue was $6.9 million versus $14.3 million a year ago, which included a $10.0 million one-time Torii milestone.
-
Runway Extended Into Q4 2027
The company unlocked the remaining $15.0 million of its $27.5 million credit facility with an entity controlled by Chairman Paul B. Manning, and now says liquidity funds operations through data readouts for both common-warts trials.
-
Loss Widened on Phase 3 Costs
Net loss was $12.4 million, or $0.58 per share, versus $0.3 million a year ago; R&D rose to $7.6 million from $2.2 million, including $3.7 million of non-cash Phase 3 costs funded by Torii.
-
Balance Sheet Still Thin
Cash was $14.4 million at September 30, 2026, down from $30.1 million at year-end 2025, and total stockholders' equity was a $6.0 million deficit.
Analysis · VRCA · Life Sciences
YCANTH net product revenue hit a record $5.7 million, up 57.9% year over year, and the company says it now has funding through both common-warts Phase 3 readouts after unlocking the remaining $15.0 million of its $27.5 million credit facility. That matters because the last 10-Q carried a going-concern warning; the runway statement pushes the financing question out to late 2027. The offset is that the quarter still lost $12.4 million and the balance sheet shows a $6.0 million stockholders' deficit, so the improvement is operating momentum rather than profitability.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VRCA was trading at $3.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $63.9M. The 52-week trading range was $3.08 to $9.82. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.